James Shannon - MannKind Corp Director
| MNKD Stock | USD 4.11 0.07 1.67% |
Director
Dr. James S. Shannon, M.D., MRCP, is an Director of the Company. He resigned as an Independent Director of MannKind Corporation effective May 1, 2012. He has more than 20 years experience at senior levels of the pharmaceutical industry and until his retirement in 2008 was Global Head of Drug Development for Novartis Pharma AG based in Basel, Switzerland. He entered the pharmaceutical industry in 1987 joining SterlingWinthrop, Inc., where he held positions of increasing responsibility in the management of Research and Development ultimately serving as Senior VicePresident, Clinical Development. In 1994 he joined Sandoz, which later became Novartis, as Head of Drug Regulatory Affairs, where he held a number of positions including Head of the Integration Office for RD overseeing the creation of the Novartis RD groups from those of Ciba and Sandoz and also Head of the Cardiovascular Strategic Team where he oversaw the design and implementation of the clinical trial program for Diovan. Subsequently he was appointed Global Head of Project Management before being appointed Global Head of Clinical Development and Medical Affairs in 1999, a position that he held until 2005 when he was appointed to Head Pharma Development. Currently Dr. Shannon is also a director of Biotie Therapies Corporationration and Endocyte, Inc. Dr. Shannon is trained in Medicine and Cardiology and received his undergraduate and postgraduate degrees at Queens University of Belfast and is a Member of the Royal College of Physicians . since 2015.
| Age | 61 |
| Tenure | 9 years |
| Address | 1 Casper Street, Danbury, CT, United States, 06810 |
| Phone | 818 661 5000 |
| Web | https://www.mannkindcorp.com |
MannKind Corp Management Efficiency
The company has return on total asset (ROA) of 0.0172 % which means that it generated a profit of $0.0172 on every $100 spent on assets. This is way below average. MannKind Corp's management efficiency ratios could be used to measure how well MannKind Corp manages its routine affairs as well as how well it operates its assets and liabilities. As of April 23, 2024, Return On Tangible Assets is expected to decline to -0.03. In addition to that, Return On Capital Employed is expected to decline to 0.03. At present, MannKind Corp's Other Current Assets are projected to increase significantly based on the last few years of reporting. The current year's Total Current Assets is expected to grow to about 392.1 M, whereas Non Current Assets Total are forecasted to decline to about 87.1 M.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Anders Brandt | Bio Techne Corp | 57 | |
| Louise Phanstiel | Verastem | 58 | |
| Alan Lewis | Biomarin Pharmaceutical | 71 | |
| Randolph Steer | Bio Techne Corp | 66 | |
| Ingrid Leisner | Bio Techne Corp | N/A | |
| Charles Dinarello | Bio Techne Corp | 73 | |
| Barbara Duncan | Adaptimmune Therapeutics Plc | 53 | |
| Tracey McCain | Kiniksa Pharmaceuticals | 50 | |
| Stephen Dilly | Sangamo Therapeutics | 58 | |
| Joseph Zakrzewski | Sangamo Therapeutics | 55 | |
| Joseph Keegan | Bio Techne Corp | 64 | |
| Roger Jeffs | Sangamo Therapeutics | 55 | |
| Brian Stuglik | Verastem | 59 | |
| Katherine Klein | United Therapeutics | 61 | |
| Elliot Sigal | Adaptimmune Therapeutics Plc | 65 | |
| Grant Chamberlain | Immutep Ltd ADR | N/A | |
| Karen Holbrook | Bio Techne Corp | 72 | |
| Kimberly Popovits | Kiniksa Pharmaceuticals | 59 | |
| Liz Anderson | Biomarin Pharmaceutical | N/A | |
| Kathryn Falberg | Biomarin Pharmaceutical | 54 | |
| Paul Friedman | Verastem | 72 | |
Management Performance
| Return On Asset | 0.0172 |
MannKind Corp Leadership Team
Elected by the shareholders, the MannKind Corp's board of directors comprises two types of representatives: MannKind Corp inside directors who are chosen from within the company, and outside directors, selected externally and held independent of MannKind. The board's role is to monitor MannKind Corp's management team and ensure that shareholders' interests are well served. MannKind Corp's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, MannKind Corp's outside directors are responsible for providing unbiased perspectives on the board's policies.
| John Bedard, Senior Affairs | ||
| Michael Friedman, Independent Director | ||
| Lauren Sabella, Executive COO | ||
| McCauley JD, Chief Officer | ||
| Raymond Urbanski, Corporate Vice President Chief Medical Officer | ||
| David Thomson, Corporate Vice President General Counsel, Corporate Secretary | ||
| Linda Adreveno, Senior Vice President - Human Resources | ||
| MS MBA, Chief Officer | ||
| Matthew PharmD, Senior Unit | ||
| Ronald Consiglio, Independent Director | ||
| Michael Castagna, Chief Commercial Officer | ||
| Joseph Kocinsky, CTO and Sr. VP of Technical Operations | ||
| Sanjay MBA, Executive Operations | ||
| Steven Binder, CFO, Principal Accounting Officer | ||
| Thomas MD, Chief Officer | ||
| Dr JD, General VP | ||
| David MacCallum, Independent Director | ||
| Burkhard MD, Executive Officer | ||
| Stuart Tross, Chief People Officer | ||
| Kent Kresa, Lead Independent Director | ||
| Alfred Mann, Founder and Executive Chairman | ||
| Rose Alinaya, Chief Accounting Officer | ||
| Juergen Martens, COO | ||
| Christine Mundkur, Director | ||
| Michael PharmD, CEO Director | ||
| Henry Nordhoff, Independent Director | ||
| Rosabel Alinaya, Acting CFO, Senior Vice President Chief Accounting Officer | ||
| Diane Palumbo, Corporate Vice President - Human Resources | ||
| Patrick McCauley, Chief Commercial Officer | ||
| James Shannon, Director | ||
| Matthew Pfeffer, Corporate Vice President and CFO |
MannKind Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is MannKind Corp a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Asset | 0.0172 | ||||
| Profit Margin | (0.06) % | ||||
| Operating Margin | 0.18 % | ||||
| Current Valuation | 1.21 B | ||||
| Shares Outstanding | 270.76 M | ||||
| Shares Owned By Insiders | 1.52 % | ||||
| Shares Owned By Institutions | 50.31 % | ||||
| Number Of Shares Shorted | 30.76 M | ||||
| Price To Earning | 2.27 X | ||||
| Price To Sales | 5.65 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards MannKind Corp in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, MannKind Corp's short interest history, or implied volatility extrapolated from MannKind Corp options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in MannKind Corp. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in industry. For information on how to trade MannKind Stock refer to our How to Trade MannKind Stock guide.You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.
Complementary Tools for MannKind Stock analysis
When running MannKind Corp's price analysis, check to measure MannKind Corp's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MannKind Corp is operating at the current time. Most of MannKind Corp's value examination focuses on studying past and present price action to predict the probability of MannKind Corp's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MannKind Corp's price. Additionally, you may evaluate how the addition of MannKind Corp to your portfolios can decrease your overall portfolio volatility.
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas |
Is MannKind Corp's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of MannKind Corp. If investors know MannKind will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about MannKind Corp listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.04) | Revenue Per Share 0.745 | Quarterly Revenue Growth 0.622 | Return On Assets 0.0172 |
The market value of MannKind Corp is measured differently than its book value, which is the value of MannKind that is recorded on the company's balance sheet. Investors also form their own opinion of MannKind Corp's value that differs from its market value or its book value, called intrinsic value, which is MannKind Corp's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because MannKind Corp's market value can be influenced by many factors that don't directly affect MannKind Corp's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between MannKind Corp's value and its price as these two are different measures arrived at by different means. Investors typically determine if MannKind Corp is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, MannKind Corp's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.